Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 709 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Decadron Clear all

Conditions: Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cemiplimab, Computed Tomography, Dexamethasone, Docetaxel, Magnetic Resonance Imaging, Ramucirumab; Procedure · Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 413
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 335 more

Conditions: Cataract
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions: Ketorolac, Dexamethasone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Lumbar Spine Disc Herniation, Lumbar Radiculitis, Lumbar Back Pain
Interventions: Dexamethasone, methylprednisolone acetate; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 21 Years to 89 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
Interventions: Gabapentin, Ketamine, Acetaminophen, Dexamethasone, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Burlington, Vermont • Colchester, Vermont

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Miami, Florida • Charleston, South Carolina + 2 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more

Conditions: Peripheral Arterial Disease
Interventions: Temsirolimus, Temsirolimus and dexamethasone sodium phosphate; Drug
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 11
States / cities: Little Rock, Arkansas • Orange, California • San Francisco, California + 7 more

Conditions: Diabetic Macular Edema
Interventions: EC-104 high dose, EC-104 low dose, Dexamethasone intravitreal implant; Drug
Lead sponsor: Eclipse Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma
Interventions: BMS-906024, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Plasma Cell Leukemia
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 11
States / cities: La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Ixazomib, Pomalidomide, Dexamethasone, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 1 more

Conditions: Leukemia, Acute Lymphoblastic Leukemia
Interventions: Rituximab, Cyclophosphamide (CTX), Doxorubicin, Vincristine, Dexamethasone, Methotrexate (MTX), Cytarabine, G-CSF, Mesna, Pegylated asparaginase, Pegfilgrastim, Solumedrol; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Size of Nasal Polyps, Control of Symptoms
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 17 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Knee Injury
Interventions: Dexamethasone, Ropivacaine; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 10 Years to 19 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Leukemia
Interventions: filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 18 Months to 29 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 135
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Mezigdomide, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 33
States / cities: Mobile, Alabama • Cerritos, California • Irvine, California + 28 more

Conditions: Perennial Allergic Rhinitis
Interventions: Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more

Conditions: Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions: Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Dasatinib, Cytarabine, Blinatumomab, Methotrexate, Mercaptopurine, Cyclophosphamide, Etoposide, Leucovorin, Intrathecal Triples, Pegaspargase, Erwinia asparaginase, Radiation; Drug · Biological · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 4 Years to 30 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: New York, New York • Memphis, Tennessee

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 31 Years
Enrollment: 5,949 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 209
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Hernia, Ventral, Pain Management
Interventions: Quadratus Lumborum (QL) Block, Placebo; Procedure
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Multiple Myeloma, Refractory
Interventions: Pembrolizumab, Belantamab mafodotin, Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey

Search by objective public record fields.

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

Dexamethasone Versus Depo Medrol in Lumbar Epidurals

Pre-Emptive Analgesia in Ano-Rectal Surgery

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Study of the Efficacy of Topical Nasal Steroids Patients With Nasal Polyps

Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.